<p>你是否在寻找股价低廉的股票？虽然有成千上万的股票每股交易价格低于 5 美元可供选择，但要找到价格低廉的赢家可能会有些困难。毕竟，每股交易价格低于 5 美元的股票被视为低价股。如果你是投资者，你会知道低价股伴随着增加的风险。</p>
<p>另一方面，如果你选择正确，投资低价股可能会带来丰厚的回报。</p>
<p>话虽如此，虽然我投资于各行各业，但我最喜欢关注的一些低价股是生物技术行业的股票。这些公司通常处于发展阶段，这为可能推动它们股价上涨的几个催化剂打开了大门。接下来，我们将讨论为什么低价股存在风险，以及我为什么喜欢投资生物技术低价股。我还将分享四个每股交易价格低于 5 美元的生物技术股票，你应该考虑现在购买。</p>
<p><strong>要点</strong></p>
<ul>
<li>低于 5 美元的股票带来额外风险，但可能带来有意义的回报。</li>
<li>我喜欢生物技术低价股，因为它们往往伴随着一长串可能推动股价上涨的催化剂。</li>
<li>MIST、RLYB、TSBX 和 LVTX 都是目前值得考虑的股票。</li>
<li>还有一只股票你应该了解，可能会带来类似英伟达的收益。阅读报告。</li>
</ul>
<h2>为什么低价股存在风险？</h2>
<p>低价股存在风险，因为它们通常代表着发展不足和无利润的公司。这些公司通常依赖投资者提供资金来开发产品。如果资金枯竭或者他们开发的产品效果不佳，这些公司可能会倒闭，导致投资者损失。</p>
<h2>为什么我喜欢生物技术低价股？</h2>
<p>生物技术低价股通常代表着生物技术公司处于发展阶段。这些公司正在研究新的潜在治疗方法或参与围绕这些治疗方法的临床试验。对我来说，这是令人兴奋的，因为这意味着可能会有几个值得期待的催化剂。一些最重要的催化剂包括：</p>
<ul>
<li><strong>招募消息</strong>：生物技术公司必须招募患者参加临床试验。代表这些公司的股票可能会在临床试验招募完成后飙升。</li>
<li><strong>新数据</strong>：围绕正在开发的生物技术产品的任何积极新数据可能推动股价上涨。</li>
<li><strong>申请提交</strong>：生物技术公司必须获得 FDA 批准销售他们开发的大部分产品。因此，FDA 的申请提交和接受可能导致收益。</li>
<li><strong>药物批准</strong>：当生物技术低价股获得新药批准时，往往会看到戏剧性的增长。</li>
</ul>
<h2>4 只每股交易价格低于 5 美元的股票现在值得购买</h2>
<p>以下是四只每股交易价格低于 5 美元的生物技术股票，可能值得加入你的投资组合：</p>
<h2>Milestone Pharmaceuticals</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1619" height="1619" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg"/></p>
<p>Milestone Pharmaceuticals（纳斯达克：MIST）是一家处于临床阶段的生物技术公司。这意味着它有研究项目已经进入临床测试阶段。该公司正在致力于开发两种与心脏节律有关的治疗方法。这些治疗方法包括心房颤动和 PSTV。</p>
<p>在心房颤动方面，Milestone Pharmaceuticals 目前正在进行 2 期临床试验。这些试验的积极数据可能会推动股价飙升。但在我看来，还有更令人兴奋的消息值得关注。</p>
<p>该公司宣布 FDA 于 2024 年 5 月 29 日接受其 CARDAMYST 的新药申请（NDA）。在接受后，FDA 将 PDUFA 日期（决定是否批准或拒绝药物的日期）定为 2025 年 3 月 26 日，距离申请被接受 10 个月。</p>
<p>考虑到这一点，可能会有几个催化剂。不仅公司 2 期临床试验的积极数据可能带来收益，任何与 CARDAMYST 潜在批准有关的消息（如委员会投票）都可能推动股价上涨。</p>
<p>分析师似乎对这种可能性感到兴奋。目前有四位分析师对该股发表意见，其中一位给予买入评级，两位给予表现优异评级，一位给予持有评级。中位数目标价为 7 美元，表明与目前每股低于 1.40 美元的价格相比，还有很大的增长空间。</p>
<h2>Rallybio 股票</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1416" height="1416" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg"/></p>
<p>Rallybio（纳斯达克：RLYB）是一家早期临床阶段的生物技术公司。这意味着该公司正在进行早期临床试验，这些试验通常用作概念验证试验。那么，为什么 Rallybio 能够进入这份值得立即购买的低价股名单？这与该公司及其投资者可能面临的催化剂数量有关。</p>
<p>该公司目前有六个正在进行的研究项目，涉及血液疾病。这些疾病包括母胎出血疾病、补体失调、贫血和代谢性疾病。该公司的两个研究项目已经进入 1 期临床试验阶段。这些项目包括 RLYB212 和 RLYB116。当然，这两个临床试验的任何积极数据都可能推动 Rallybio 股价上涨。</p>
<p>值得注意的是，该公司还有两个处于临床前阶段的项目——在将治疗方法测试于人类之前进行进一步研究的阶段。该公司还有两个项目处于发现阶段。</p>
<p>由于围绕潜在治疗方法的六个进行中项目，该公司在短期内发布数据的可能性相对较高。由于这些数据有可能推动股价飙升，这只股票值得密切关注。</p>
<p>分析师们对这支股票也持乐观态度。其中三位将其评为买入，两位评为表现优异，一位评为持有。中位数价格目标为 12 美元，这表明相较于目前接近 1.20 美元的股价，股票有显著的增长潜力。</p>
<h2>Turnstone Biologics</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1366" height="768" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg"/></p>
<p>Turnstone Biologics（纳斯达克：TSBX）是一家早期临床阶段的生物技术公司，主要专注于固体肿瘤的治疗。这一点很重要，因为即使在近几十年来肿瘤学领域取得了巨大进展，固体肿瘤癌症在晚期仍然有很高的死亡率。</p>
<p>该公司目前有四个研究项目，其中两个处于第一阶段临床试验阶段，另外两个处于临床前开发阶段。拥有四个正在进行中的项目，可能会迎来几个催化剂。毕竟，围绕公司候选药物的任何积极数据都可能导致股票价值的显著增长。</p>
<p>而增长正是分析师们预期看到的。目前有三位分析师对 TSBX 发表意见，其中一位将其评为买入，一位评为表现优异，一位评为持有。每股 12 美元的中位数价格目标表明，该股票在未来一年内可能上涨超过 400%。</p>
<h2>Lava Therapeutics</h2>
<p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1366" height="768" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg"/></p>
<p>Lava Therapeutics（纳斯达克：LVTX）是另一家早期临床阶段的肿瘤学公司。与 Turnstone Biologics 类似，该公司正在开发设计精准聚焦于肿瘤活动的 T 细胞疗法。</p>
<p>Lava Therapeutics 目前有五个正在进行中的临床和临床前研究项目。其中两个项目，LAVA-1207 和 PF-08046052，正在进行第一阶段临床试验。值得一提的是，后者是与辉瑞合作的试验，辉瑞是在潜在的固体肿瘤治疗领域领先的制药公司。除了这些项目，该公司还有专注于血液恶性肿瘤和三个未公开透露适应症的临床前项目。</p>
<p>与名单上任何公司一样，与 Lava Therapeutics 研发治疗药物相关的任何积极消息都可能推动股价飙升。也许这就是为什么分析师对 LVTX 持如此积极的看法。</p>
<p>目前有四位分析师对 LVTX 进行覆盖。其中两位将其评为买入，另外两位评为表现优异。目前的中位数价格目标为 5.57 美元。考虑到每股 1.84 美元的当前价格，如果分析师们正确的话，股票在未来一年内可能会多次增长。</p>
<h2>“下一个英伟达” 可能改变你的生活</h2>
<p>如果你错过了英伟达的历史性增长，那么从人工智能中获得改变生活的利润的机会并没有结束。</p>
<p>2009 年首次预测了英伟达人工智能崛起的 24/7 华尔街分析师刚刚发布了一份名为 “下一个英伟达” 的全新研究报告。</p>
<p>点击这里下载您的免费副本。</p>
<p>这篇文章最初发表在 24/7 华尔街。</p>

MIST

<p>4 家股价低于 5 美元的生物科技股，值得考虑投资。Milestone Pharmaceuticals 是一家处于临床阶段的生物科技公司，其药物在临床试验和 FDA 批准方面具有潜在的催化剂。分析师对其前景持乐观态度</p>

<p>Are you looking for stocks to buy with low price tags? While there are thousands of stocks that trade for under $5 per share to choose from, it can be difficult to find winners with low sticker prices. After all, stocks that trade for under $5 per share are considered penny stocks. And if you’re an investor, you know that penny stocks come with increased risk.</p>
<div class="lb-trans"><p>你是否在寻找股价低廉的股票？虽然有成千上万的股票每股交易价格低于 5 美元可供选择，但要找到价格低廉的赢家可能会有些困难。毕竟，每股交易价格低于 5 美元的股票被视为低价股。如果你是投资者，你会知道低价股伴随着增加的风险。</p>
</div><p>On the other hand, penny stock investments can be fruitful if you make the right picks.</p>
<div class="lb-trans"><p>另一方面，如果你选择正确，投资低价股可能会带来丰厚的回报。</p>
</div><p>With that said, while I do invest in various industries, some of my favorite penny stocks to follow are in the biotechnology industry. These companies are usually in the development stages, which opens the door to several catalysts that could send their prices up. Below, we’ll talk about why penny stocks are risky and why I like investing in biotech penny stocks. I’ll also share four biotech picks trading under $5 per share that you should consider buying now.</p>
<div class="lb-trans"><p>话虽如此，虽然我投资于各行各业，但我最喜欢关注的一些低价股是生物技术行业的股票。这些公司通常处于发展阶段，这为可能推动它们股价上涨的几个催化剂打开了大门。接下来，我们将讨论为什么低价股存在风险，以及我为什么喜欢投资生物技术低价股。我还将分享四个每股交易价格低于 5 美元的生物技术股票，你应该考虑现在购买。</p>
</div><p><strong>Key Points</strong></p>
<ul>
<li>Stocks under $5 come with added risk but can produce meaningful returns.</li>
<li>I enjoy biotech penny stocks, as they tend to come with a laundry list of catalysts that could send them higher.</li>
<li>MIST, RLYB, TSBX, and LVTX are all stocks that are worth considering right now.</li>
<li>There’s another stock pick you should know about that can produce NVIDIA-like gains. Read the report here.</li>
</ul>
<div class="lb-trans"><p><strong>要点</strong></p>
<ul>
<li>低于 5 美元的股票带来额外风险，但可能带来有意义的回报。</li>
<li>我喜欢生物技术低价股，因为它们往往伴随着一长串可能推动股价上涨的催化剂。</li>
<li>MIST、RLYB、TSBX 和 LVTX 都是目前值得考虑的股票。</li>
<li>还有一只股票你应该了解，可能会带来类似英伟达的收益。阅读报告。</li>
</ul>
</div><h2>Why Are Penny Stocks Risky?</h2>
<div class="lb-trans"><h2>为什么低价股存在风险？</h2>
</div><p>Penny stocks are risky because they typically represent underdeveloped and unprofitable companies. These companies typically rely on investors to provide the funding they need to develop products. If that funding dries up or the products they develop don’t work well, these companies could fail, leading to losses for their investors.</p>
<div class="lb-trans"><p>低价股存在风险，因为它们通常代表着发展不足和无利润的公司。这些公司通常依赖投资者提供资金来开发产品。如果资金枯竭或者他们开发的产品效果不佳，这些公司可能会倒闭，导致投资者损失。</p>
</div><h2>Why I Like Biotechnology Penny Stocks</h2>
<div class="lb-trans"><h2>为什么我喜欢生物技术低价股？</h2>
</div><p>Biotechnology penny stocks typically represent biotechnology companies in the development phases. These companies are either researching new potential treatments or taking part in clinical trials surrounding those treatments. That’s exciting for me since that means there may be several catalysts to look forward to. Some of the most important catalysts to watch out for include:</p>
<ul>
<li><strong>Enrollment News</strong>: Biotechnology companies must enroll patients into clinical trials. The stocks that represent these companies may spike upon the completion of enrollment for a clinical trial.</li>
<li><strong>New Data</strong>: Any positive new data surrounding a biotechnology product in development could send the price of the stock up.</li>
<li><strong>Application Submissions</strong>: Biotechnology companies must receive FDA approval to sell the majority of the products they develop. As such, FDA application submissions and acceptance can lead to gains.</li>
<li><strong>Drug Approvals</strong>: Biotech penny stocks often see dramatic gains when they achieve new drug approvals.</li>
</ul>
<div class="lb-trans"><p>生物技术低价股通常代表着生物技术公司处于发展阶段。这些公司正在研究新的潜在治疗方法或参与围绕这些治疗方法的临床试验。对我来说，这是令人兴奋的，因为这意味着可能会有几个值得期待的催化剂。一些最重要的催化剂包括：</p>
<ul>
<li><strong>招募消息</strong>：生物技术公司必须招募患者参加临床试验。代表这些公司的股票可能会在临床试验招募完成后飙升。</li>
<li><strong>新数据</strong>：围绕正在开发的生物技术产品的任何积极新数据可能推动股价上涨。</li>
<li><strong>申请提交</strong>：生物技术公司必须获得 FDA 批准销售他们开发的大部分产品。因此，FDA 的申请提交和接受可能导致收益。</li>
<li><strong>药物批准</strong>：当生物技术低价股获得新药批准时，往往会看到戏剧性的增长。</li>
</ul>
</div><h2>4 Stocks Under $5 to Buy Now</h2>
<div class="lb-trans"><h2>4 只每股交易价格低于 5 美元的股票现在值得购买</h2>
</div><p>Here are four biotechnology stocks trading under $5 that may be worth adding to your investment portfolio:</p>
<div class="lb-trans"><p>以下是四只每股交易价格低于 5 美元的生物技术股票，可能值得加入你的投资组合：</p>
</div><h2>Milestone Pharmaceuticals</h2>
<div class="lb-trans"><h2>Milestone Pharmaceuticals</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2015/10/thinkstockphotos-101538677.jpg"/></p>
<p>Milestone Pharmaceuticals (Nasdaq: MIST) is a clinical-stage biotechnology company. That means it has research programs that have made it to clinical testing. The company is working to develop treatments for two indications, both of which have to do with the rhythm of the heart. Those indications include atrial fibrillation and PSTV.</p>
<div class="lb-trans"><p>Milestone Pharmaceuticals（纳斯达克：MIST）是一家处于临床阶段的生物技术公司。这意味着它有研究项目已经进入临床测试阶段。该公司正在致力于开发两种与心脏节律有关的治疗方法。这些治疗方法包括心房颤动和 PSTV。</p>
</div><p>On the atrial fibrillation side of the coin, Milestone Pharmaceuticals is currently taking part in Phase 2 clinical trials. Positive data from those trials could send the stock on a run for the top. But in my opinion, there’s even more exciting news to watch for.</p>
<div class="lb-trans"><p>在心房颤动方面，Milestone Pharmaceuticals 目前正在进行 2 期临床试验。这些试验的积极数据可能会推动股价飙升。但在我看来，还有更令人兴奋的消息值得关注。</p>
</div><p>The company announced that the FDA accepted its New Drug Application (NDA) for CARDAMYST on May 29, 2024. Upon acceptance, the FDA set the PDUFA date (the date by which it must decide whether to approve or deny the drug) to March 26, 2025, 10 months following the acceptance of the application.</p>
<div class="lb-trans"><p>该公司宣布 FDA 于 2024 年 5 月 29 日接受其 CARDAMYST 的新药申请（NDA）。在接受后，FDA 将 PDUFA 日期（决定是否批准或拒绝药物的日期）定为 2025 年 3 月 26 日，距离申请被接受 10 个月。</p>
</div><p>With that in mind, several catalysts may be ahead. Not only could positive data from the company’s Phase 2 clinical trial lead to gains, but any news (like a committee vote) having to do with the potential approval of CARDAMYST could send the stock up.</p>
<div class="lb-trans"><p>考虑到这一点，可能会有几个催化剂。不仅公司 2 期临床试验的积极数据可能带来收益，任何与 CARDAMYST 潜在批准有关的消息（如委员会投票）都可能推动股价上涨。</p>
</div><p>Analysts seem to be excited about that possibility. Four analysts are currently weighing in on the stock, one who rates it a Buy, two who rate it an Outperform, and one who rates it a Hold. The median price target is $7, suggesting that there’s plenty of room for growth from the current price of under $1.40 per share.</p>
<div class="lb-trans"><p>分析师似乎对这种可能性感到兴奋。目前有四位分析师对该股发表意见，其中一位给予买入评级，两位给予表现优异评级，一位给予持有评级。中位数目标价为 7 美元，表明与目前每股低于 1.40 美元的价格相比，还有很大的增长空间。</p>
</div><h2>Rallybio Stock</h2>
<div class="lb-trans"><h2>Rallybio 股票</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2015/11/thinkstockphotos-474151326.jpg"/></p>
<p>Rallybio (Nasdaq: RLYB) is an early clinical-stage biotechnology company. That means the company is working on early clinical trials which are generally used as proof-of-concept trials. So, why did Rallybio make it to this list of stocks under $5 to buy right now? It has to do with the number of catalysts that could be ahead for the company and its investors.</p>
<div class="lb-trans"><p>Rallybio（纳斯达克：RLYB）是一家早期临床阶段的生物技术公司。这意味着该公司正在进行早期临床试验，这些试验通常用作概念验证试验。那么，为什么 Rallybio 能够进入这份值得立即购买的低价股名单？这与该公司及其投资者可能面临的催化剂数量有关。</p>
</div><p>The company currently has six ongoing research programs addressing blood disorders. Those disorders include maternal-fetal bleed disorders, complement dysregulation, anemia, and metabolic disorders. Two of the company’s research programs have already made it to Phase 1 clinical trials. Those include RLYB212 and RLYB116. Of course, any positive data from these two clinical trials could send Rallybio shares up.</p>
<div class="lb-trans"><p>该公司目前有六个正在进行的研究项目，涉及血液疾病。这些疾病包括母胎出血疾病、补体失调、贫血和代谢性疾病。该公司的两个研究项目已经进入 1 期临床试验阶段。这些项目包括 RLYB212 和 RLYB116。当然，这两个临床试验的任何积极数据都可能推动 Rallybio 股价上涨。</p>
</div><p>It’s also worth noting that the company has two programs in the preclinical phases — the phases in which further research is done before testing the treatments on humans. The company also has two programs in the discovery phases.</p>
<div class="lb-trans"><p>值得注意的是，该公司还有两个处于临床前阶段的项目——在将治疗方法测试于人类之前进行进一步研究的阶段。该公司还有两个项目处于发现阶段。</p>
</div><p>With six ongoing programs surrounding potential therapeutics, the likelihood that the company will release data in the near term is relatively high. Since that data has the potential to send the stock on a run for the top, this stock is well worth watching.</p>
<div class="lb-trans"><p>由于围绕潜在治疗方法的六个进行中项目，该公司在短期内发布数据的可能性相对较高。由于这些数据有可能推动股价飙升，这只股票值得密切关注。</p>
</div><p>Analysts are also bullish on the stock. Three of them rate the stock a Buy, two rate it an Outperform, and one rates it a Hold. The median price target is $12, pointing to significant potential growth over the current stock price that’s just shy of $1.20.</p>
<div class="lb-trans"><p>分析师们对这支股票也持乐观态度。其中三位将其评为买入，两位评为表现优异，一位评为持有。中位数价格目标为 12 美元，这表明相较于目前接近 1.20 美元的股价，股票有显著的增长潜力。</p>
</div><h2>Turnstone Biologics</h2>
<div class="lb-trans"><h2>Turnstone Biologics</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2018/07/thinkstockphotos-601373580.jpg"/></p>
<p>Turnstone Biologics (Nasdaq: TSBX) is an early clinical-stage biotech company with a central focus on the treatment of solid tumors. That’s important because solid tumor cancers typically have high mortality rates in late stages, even with the vast advancements that have been made in the field of oncology in recent decades.</p>
<div class="lb-trans"><p>Turnstone Biologics（纳斯达克：TSBX）是一家早期临床阶段的生物技术公司，主要专注于固体肿瘤的治疗。这一点很重要，因为即使在近几十年来肿瘤学领域取得了巨大进展，固体肿瘤癌症在晚期仍然有很高的死亡率。</p>
</div><p>The company currently has four research programs, two of which are in Phase 1 clinical trials and two of which are in preclinical development phases. With four ongoing programs, several catalysts could be ahead. After all, any positive data surrounding the company’s candidates could lead to significant gains in the value of the stock.</p>
<div class="lb-trans"><p>该公司目前有四个研究项目，其中两个处于第一阶段临床试验阶段，另外两个处于临床前开发阶段。拥有四个正在进行中的项目，可能会迎来几个催化剂。毕竟，围绕公司候选药物的任何积极数据都可能导致股票价值的显著增长。</p>
</div><p>And growth is exactly what analysts are expecting to see. Three analysts are currently weighing in on TSBX, one of whom rates the stock a Buy, one who rates it an Outperform, and one who rates it a Hold. The median price target of $12 per share suggests that the stock could climb more than 400% in the next year.</p>
<div class="lb-trans"><p>而增长正是分析师们预期看到的。目前有三位分析师对 TSBX 发表意见，其中一位将其评为买入，一位评为表现优异，一位评为持有。每股 12 美元的中位数价格目标表明，该股票在未来一年内可能上涨超过 400%。</p>
</div><h2>Lava Therapeutics</h2>
<div class="lb-trans"><h2>Lava Therapeutics</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg" alt="" original-src="https://247wallst.com/wp-content/uploads/2018/01/dangerous-drugs-e1534767559507.jpg"/></p>
<p>Lava Therapeutics (Nasdaq: LVTX) is another early clinical-stage oncology company. Like Turnstone Biologics, the company is developing T-cell therapies that are designed to precisely focus on tumor activity.</p>
<div class="lb-trans"><p>Lava Therapeutics（纳斯达克：LVTX）是另一家早期临床阶段的肿瘤学公司。与 Turnstone Biologics 类似，该公司正在开发设计精准聚焦于肿瘤活动的 T 细胞疗法。</p>
</div><p>Lava Therapeutics currently has five ongoing clinical and preclinical research programs. Two of those programs, LAVA-1207 and PF-08046052, are in Phase 1 clinical trials. It’s also worth noting that the latter is a trial in partnership with Pfizer, the leading pharmaceutical company in the potential treatment of solid tumors. Outside of these programs, the company has preclinical programs focused on hematological malignancies and three undisclosed indications.</p>
<div class="lb-trans"><p>Lava Therapeutics 目前有五个正在进行中的临床和临床前研究项目。其中两个项目，LAVA-1207 和 PF-08046052，正在进行第一阶段临床试验。值得一提的是，后者是与辉瑞合作的试验，辉瑞是在潜在的固体肿瘤治疗领域领先的制药公司。除了这些项目，该公司还有专注于血液恶性肿瘤和三个未公开透露适应症的临床前项目。</p>
</div><p>As is the case with any company on this list, any positive news having to do with Lava Therapeutics research and development therapeutics could send the stock to the top. Perhaps that’s why analysts have such a positive opinion of LVTX.</p>
<div class="lb-trans"><p>与名单上任何公司一样，与 Lava Therapeutics 研发治疗药物相关的任何积极消息都可能推动股价飙升。也许这就是为什么分析师对 LVTX 持如此积极的看法。</p>
</div><p>Four analysts currently cover LVTX. Two of them rate it a Buy, while the other two rate it an Outperform. The median price target is currently $5.57. Considering the current price of $1.84 per share, the stock could gain in multiples over the next year if analysts are correct.</p>
<div class="lb-trans"><p>目前有四位分析师对 LVTX 进行覆盖。其中两位将其评为买入，另外两位评为表现优异。目前的中位数价格目标为 5.57 美元。考虑到每股 1.84 美元的当前价格，如果分析师们正确的话，股票在未来一年内可能会多次增长。</p>
</div><h2>“The Next NVIDIA” Could Change Your Life</h2>
<div class="lb-trans"><h2>“下一个英伟达” 可能改变你的生活</h2>
</div><p>If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.</p>
<div class="lb-trans"><p>如果你错过了英伟达的历史性增长，那么从人工智能中获得改变生活的利润的机会并没有结束。</p>
</div><p>The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”</p>
<div class="lb-trans"><p>2009 年首次预测了英伟达人工智能崛起的 24/7 华尔街分析师刚刚发布了一份名为 “下一个英伟达” 的全新研究报告。</p>
</div><p>Click here to download your FREE copy.</p>
<div class="lb-trans"><p>点击这里下载您的免费副本。</p>
</div><p>The post 4 Stocks Under $5 To Buy Now appeared first on 24/7 Wall St..</p>
<div class="lb-trans"><p>这篇文章最初发表在 24/7 华尔街。</p>
</div>

现在可以买入的 4 只 5 美元以下的股票